DSpace Repository

Ten-year safety with polyacrylamide gel used to correct facial lipoatrophy in HIV-infected patients

Show simple item record

dc.contributor Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades
dc.contributor.author Negredo, Eugenia
dc.contributor.author Puig, Jordi
dc.contributor.author Ornelas, Arelly
dc.contributor.author Echeverria, Patricia
dc.contributor.author Bonjoch, Anna
dc.contributor.author Estany, Carla
dc.contributor.author Higueras, Carmen
dc.contributor.author Gonzalez-Mestre, Vicente
dc.contributor.author Clotet, Bonaventura
dc.date.accessioned 2015-11-10T09:18:36Z
dc.date.available 2015-11-10T09:18:36Z
dc.date.created 2015
dc.date.issued 2015
dc.identifier.citation Negredo, E., Puig, J., Ornelas, A., Echeverría, P., Bonjoch, A., Estany, C., et al. (2015). Ten-year safety with polyacrylamide gel used to correct facial lipoatrophy in HIV-infected patients. AIDS Research and Human Retroviruses, 31(8), 817-821. ca_ES
dc.identifier.issn 1931-8405
dc.identifier.uri http://hdl.handle.net/10854/4343
dc.description.abstract Long-term results ( > 5 years) for synthetic substances used to repair facial lipoatrophy have not been published. We performed a cross-sectional study to evaluate the 10-year safety of polyacrylamide hydrogel (Aquamid) among the 751 patients from our unit who received facial infiltrations at least 10 years ago. Epidemiological and clinical data such as complications and patient satisfaction were collected. We also identified those patients who presented a facial infection at any time after infiltration. A total of 104 patients had received Aquamid at least 10 years ago. Before infiltrations, 24.0%, 41.3%, and 34.7% presented very severe, severe, and moderate facial lipoatrophy, respectively. After a mean (SD) of 10.3 (0.5) years since the infiltrations, 19.2%, 47.7%, and 31.7% of patients reported moderate, mild, and no signs of facial lipoatrophy. The values reported by physicians for the same categories were 1.9%, 10.6%, and 87.5%. Indurations were detected in 6.7% of patients and nodules in 3.8%. Five patients (4.8%) had a local infection. A further 15 patients with a shorter follow-up (less than 10 years) presented local infections (overall incidence considering the 751 patients who received infiltrations of Aquamid, 2.7%); the product had to be withdrawn in three cases. The majority of patients were highly satisfied (74.8%) or satisfied (23.4%) with the cosmetic results; among patients with severe or very severe lipoatrophy at baseline, 31.4% were satisfied and 65.7% were highly satisfied. Infiltrations with polyacrylamide hydrogel (Aquamid) are a safe strategy for the treatment of facial lipoatrophy in the long term. The rate of severe complications was low, and patient satisfaction with the cosmetic results was high. However, facial infections may appear in the long term. Therefore, HIV-infected patients who received synthetic substances should be carefully monitored over time. ca_ES
dc.format application/pdf
dc.format.extent 6 p. ca_ES
dc.language.iso eng ca_ES
dc.publisher Mary Ann Liebert ca_ES
dc.rights Tots els drets reservats ca_ES
dc.rights (c) Mary Ann Liebert
dc.subject.other Sida -- Tractament ca_ES
dc.subject.other VIH (Virus) ca_ES
dc.title Ten-year safety with polyacrylamide gel used to correct facial lipoatrophy in HIV-infected patients ca_ES
dc.type info:eu-repo/semantics/article ca_ES
dc.identifier.doi https://doi.org/10.1089/aid.2015.0004
dc.rights.accesRights info:eu-repo/semantics/closedAccess ca_ES
dc.type.version info:eu-repo/publishedVersion ca_ES
dc.indexacio Indexat a WOS/JCR ca_ES
dc.indexacio Indexat a SCOPUS ca_ES

Files in this item

Show simple item record

Search RIUVic